AIDSWEEKLY Plus; Monday, March 2, 2009
Staff Medical Writers

NewsRx -- New research at Oregon Health & Science University's Vaccine and Gene Therapy Institute suggests vaccines that specifically target HIV in the initial stages of infection before it becomes a rapidly replicating, system-wide infection - may be a successful approach in limiting the spread of the disease. The research is published in the early online edition of the journal Nature Medicine and will appear in a future printed edition (see also Oregon Health & Science University).

The researchers used a vaccination method that involves creating and maintaining resistance by programming a portion of the body's immune system – effector memory T-cells – to look out for HIV at the site of infection.

"HIV appears to be vulnerable when it is first introduced into mucosal surfaces in the body," said Louis Picker, M.D., associate director of the OHSU VGTI and director of the VGTI's vaccine program. "However, once HIV spreads throughout the entire body, it replicates very rapidly and becomes difficult if not impossible to control. Our approach is to attack during this early period of vulnerability. The approach is similar to that of a homeowner who sprays their house with water before sparks land on the roof. This approach can prevent the roof from catching fire and, in the case of HIV, prevent the spread of the virus."

To determine whether they could proactively "educate" the immune system, scientists used a monkey model of AIDS - simian immunodeficiency virus (SIV) – the monkey counterpart to HIV. They introduced an altered monkey form of cytomegalovirus (CMV) programmed to express SIV proteins and trigger specialized effector memory T-cells to look for and attack SIV in its early stages.

In total, 12 rhesus macaque monkeys at the Oregon National Primate Research Center were vaccinated using this method. When the animals were later infected with SIV, one-third were protected.

The next step for the research team is to try to determine why only a portion of the monkeys who are vaccinated using this method are responding. The researchers also hope to expand the number of subjects to better determine the success rate of the therapy.

Keywords: HIV/AIDS Co-Infection, AIDS, Acquired Immunodeficiency Syndrome, Biotechnology, HIV, Human Immunodeficiency Virus Viral Infection, Immunization, Therapy, Treatment, Vaccination, Vaccines, Virology, Oregon Health & Science University.

This article was prepared by AIDS Weekly editors from staff and other reports.

Ref: Picker LJ, et al., “Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge”, Nat Med. 2009 Mar;15(3):293-9.

2009-03-02
AW090301

Copyright © 2009 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the Elton John AIDS Foundation UK, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.